The Genomics Shared Resource (GSR) provides comprehensive services and expertise in the area of genomics and data analysis and bioinformatics. The GSR provides Cancer Center researchers with direct access to the most contemporary genomic applications and state-of-the-art instrumentation for next-generation sequencing (NGS), microarray analyses, and NanoString nCounter analyses. This includes Illumina NGS systems (MiSeq, HiSeq 2500, 3000, 4000), multi-platform microarray processing equipment for Affymetrix, Agilent, and Illumina microarrays, and the required computational hardware and software systems. Together, these enable investigators to accomplish virtually every type of application for transcriptomics, genome sequencing, epigenomics, and metagenomics, including whole transcriptome analysis, genome-wide profiling of single nucleotide variants, copy number analysis, mapping of long-range interactions of DNA regions, and molecular characterization of infectious agents. These are generally provided as completely comprehensive, sample-to-results services in that investigators need only provide RNA or DNA samples, and the GSR will perform all downstream technical processing, as well as data analysis. Ancillary services for DNA/RNA isolation, quality assessment, and sample acquisition are also provided. To complement these services and to help achieve productive outcomes from genomics experiments, the GSR provides extensive data analysis and integrative bioinformatics support, and routinely assists in the preparation of the appropriate sections of manuscripts and grant proposals. Additionally, education is an important component of the GSR and is provided through training, workshops, and seminars. Unique aspects of the GSR include a strong emphasis on facilitating translational science and the custom development of protocols and reagents to address the specific goals of investigators' experiments. For translational applications, the GSR has developed and optimized protocols enabling the analysis of samples obtained from clinical specimens, such as whole blood, serum/plasma, and FFPE specimens. Investigator-driven research often requires protocols and tools to be adapted or newly developed. These include modified sequencing library preparations and target enrichment panels for mutation screening of tumors and oncogenic viruses. Moreover, the GSR strives to introduce new technologies, such as single-cell sequencing and to serve as a pipeline for clinical applications of genomics. Taken together, the GSR provides a complete integrative and functional molecular profiling solution to the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-17
Application #
9773653
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
17
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529

Showing the most recent 10 out of 836 publications